271 related articles for article (PubMed ID: 25535816)
1. Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Nozzoli C; Staderini M; Veltroni A; Longo G; Bacchiarri F; Donnini I; Guarrera A; Bosi A
Leuk Lymphoma; 2015; 56(8):2388-91. PubMed ID: 25535816
[TBL] [Abstract][Full Text] [Related]
2. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
Touzeau C; Blin N; Clavert A; Roland V; Loirat M; Tessoulin B; Le Gouill S; Planche L; Pennetier M; Mahe B; Mohty M; Malard F; Peterlin P; Dubruille V; Moreau P
Leuk Lymphoma; 2012 Jul; 53(7):1318-20. PubMed ID: 22211836
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Alegre A; Oriol-Rocafiguera A; Garcia-Larana J; Mateos MV; Sureda A; Martinez-Chamorro C; Cibeira MT; Aguado B; Knight R; Rosettani B
Leuk Lymphoma; 2012 Sep; 53(9):1714-21. PubMed ID: 22292853
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience.
Soyer N; Patır P; Uysal A; Duran M; Ünal HD; Durusoy R; Tombuloğlu M; Şahin F; Töbü M; Vural F; Saydam G
Turk J Med Sci; 2018 Aug; 48(4):777-785. PubMed ID: 30119153
[TBL] [Abstract][Full Text] [Related]
11. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
[TBL] [Abstract][Full Text] [Related]
12. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
Dimopoulos MA; Palumbo A; Attal M; Beksaç M; Davies FE; Delforge M; Einsele H; Hajek R; Harousseau JL; da Costa FL; Ludwig H; Mellqvist UH; Morgan GJ; San-Miguel JF; Zweegman S; Sonneveld P;
Leukemia; 2011 May; 25(5):749-60. PubMed ID: 21293488
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
[TBL] [Abstract][Full Text] [Related]
15. How lenalidomide is changing the treatment of patients with multiple myeloma.
Dimopoulos MA; Terpos E; Niesvizky R
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
[TBL] [Abstract][Full Text] [Related]
16. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Zago M; Oehrlein K; Rendl C; Hahn-Ast C; Kanz L; Weisel K
Ann Hematol; 2014 Dec; 93(12):1993-9. PubMed ID: 24974802
[TBL] [Abstract][Full Text] [Related]
18. Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.
Alahmadi M; Masih-Khan E; Atenafu EG; Chen C; Kukreti V; Tiedemann R; Trudel S; Reece DE
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e195-e203. PubMed ID: 30723035
[TBL] [Abstract][Full Text] [Related]
19. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
Knauf W; Aldaoud A; Losem C; Mittermueller J; Neise M; Niemeier B; Harde J; Trarbach T; Potthoff K
Leuk Res; 2018 May; 68():90-97. PubMed ID: 29579627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
